论文部分内容阅读
目的:观察替米沙坦联合百灵胶囊治疗早期2型糖尿病(T2DN)肾病临床疗效。方法:46例T2DN患者随机分为2组,各23例。对照组给予口服替米沙坦片治疗;观察组在对照组治疗基础上给予百灵胶囊治疗。疗程3月。观察2组治疗前后微量白蛋白排泄率(UAE)、血钾(K)、血肌酐(SCr)指标。结果:2组治疗前后SCr、K比较,差异无统计学意义(P>0.05);2组治疗前后UAE均改变明显,与本组治疗前比较,差异有统计学意义(P<0.05);治疗后观察组UAE明显低于对照组,2组比较,差异有统计学意义(P<0.05)。结论:替米沙坦联合百灵胶囊对早期T2DN能够明显的降低患者的蛋白尿排出量,增加其疗效。
Objective: To observe the clinical efficacy of telmisartan combined with Braun capsule in the treatment of early type 2 diabetes mellitus (T2DN) nephropathy. Methods: 46 patients with T2DM were randomly divided into two groups, 23 cases each. The control group was treated with telmisartan. The observation group was treated with Bailing capsule on the basis of the control group. Treatment in March. The levels of albumin excretion (UAE), serum potassium (K) and serum creatinine (SCr) before and after treatment were observed in two groups. Results: There was no significant difference in SCr, K between the two groups before and after treatment (P> 0.05). The UAE in both groups changed significantly before treatment and after treatment, the difference was statistically significant (P <0.05) After the observation group UAE was significantly lower than the control group, the two groups, the difference was statistically significant (P <0.05). Conclusion: Telmisartan combined with Bailing Capsule can significantly reduce the proteinuria in patients with early T2DN and increase its efficacy.